Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 3/20 | 0.77 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.77 |
| ▸ | LGALS4 | P56470 | 3/20 | 0.77 |
| ▸ | GJB2 | P29033 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | GBA1 | P04062 | 1/20 | 0.50 |
| ▸ | SELL | P14151 | 2/20 | 0.49 |
| ▸ | SELP | P16109 | 2/20 | 0.49 |
| ▸ | CETP | P11597 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18373266 | 1.00 | LGALS8 (0.77) | LGALS8LGALS3LGALS4GJB2MAPK1 | |
| SCHEMBL18357280 | 1.00 | LGALS8 (0.77) | LGALS8LGALS3LGALS4GJB2MAPK1 | |
| SCHEMBL13109610 | 1.00 | LGALS8 (0.77) | LGALS8LGALS3LGALS4GJB2MAPK1 | |
| SCHEMBL22067762 | 1.00 | LGALS8 (0.77) | LGALS8LGALS3LGALS4GJB2MAPK1 | |
| SCHEMBL25005884 | 1.00 | LGALS8 (0.77) | LGALS8LGALS3LGALS4GJB2MAPK1 | |
| SCHEMBL22067763 | 1.00 | LGALS8 (0.77) | LGALS8LGALS3LGALS4GJB2MAPK1 | |
| SCHEMBL23183598 | 1.00 | LGALS8 (0.77) | LGALS8LGALS3LGALS4GJB2MAPK1 | |
| SCHEMBL21068067 | 1.00 | LGALS8 (0.77) | LGALS8LGALS3LGALS4GJB2MAPK1 | |
| SCHEMBL23393554 | 1.00 | LGALS8 (0.77) | LGALS8LGALS3LGALS4GJB2MAPK1 | |
| SCHEMBL22431206 | 1.00 | LGALS8 (0.77) | LGALS8LGALS3LGALS4GJB2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637275-B2 | Postprandial hyperglycemia marker, method of measuring the same, and usage thereof | ARKRAY, INC. (JP) | 2014-01-28 | — | — | US | disclosed |
| US-20100190194-A1 | POSTPRANDIAL HYPERGLYCEMIA MARKER, METHOD OF MEASURING THE SAME, AND USAGE THEREOF | ARKRAY, INC. (JP) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190194-A1 | POSTPRANDIAL HYPERGLYCEMIA MARKER, METHOD OF MEASURING THE SAME, AND USAGE THEREOF | PREP, AGL, HBB | LGALS8 618/4885LGALS3 401/4885LGALS4 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.